Omeros | OMER - Debt


Omeros reported $442.16M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 727.89M 163.33M Dec/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 60.85B 78M Sep/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xoma USD 120.79M 3.27M Jun/2024